Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 2185 participants.
Also called NCT01351675
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,185 participants
- Sponsor
- Registry
-
NCT01351675
-
- Other papers using this trial's data
- Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01351675. Randomized; quadruple masking; primary purpose treatment. Start 2011-06-30 (actual); primary completion 2012-10-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Acronym
- BEACON
- Condition
- Renal Insufficiency, Chronic
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Bardoxolone Methyl: 20 mg
- Lead sponsor
- Biogen
Record details
- Record id
cardio:ct-nct01351675- Content hash
75b38e8e7ed0acae8efede32716cfcaa6d9d68119a30c86f13610926a8108594